HomeCORT • NASDAQ
add
Corcept Therapeutics Incorporated
Nakaraang pagsara
$54.79
Sakop ng araw
$51.51 - $55.22
Sakop ng taon
$20.84 - $61.66
Market cap
5.43B USD
Average na Volume
1.12M
P/E ratio
40.82
Dividend yield
-
Primary exchange
NASDAQ
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | 182.55M | 47.69% |
Gastos sa pagpapatakbo | 133.08M | 46.60% |
Net na kita | 47.21M | 50.47% |
Net profit margin | 25.86 | 1.85% |
Kita sa bawat share | 0.41 | 46.43% |
EBITDA | 46.92M | 49.37% |
Aktuwal na % ng binabayarang buwis | 10.82% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 380.34M | 7.07% |
Kabuuang asset | 784.26M | 32.02% |
Kabuuang sagutin | 145.42M | 9.88% |
Kabuuang equity | 638.84M | — |
Natitirang share | 104.78M | — |
Presyo para makapag-book | 8.98 | — |
Return on assets | 15.54% | — |
Return on capital | 18.68% | — |
Cash Flow
Net change in cash
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 47.21M | 50.47% |
Cash mula sa mga operasyon | 73.83M | 39.54% |
Cash mula sa pag-invest | -44.04M | 59.81% |
Cash mula sa financing | -21.09M | -438.61% |
Net change in cash | 8.70M | 114.36% |
Malayang cash flow | 70.22M | 28.78% |
Tungkol
Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD. Wikipedia
Itinatag
May 13, 1998
Headquarters
Website
Mga Empleyado
352
